Cure8 news brief
The Phase 2b results suggest the investigational TL1A drug duvakitug improved clinical and endoscopic outcomes versus placebo in both ulcerative colitis and Crohn’s disease, which could expand future treatment options if later trials confirm benefit and safety.
Adults with Crohn’s disease or ulcerative colitis, patients who have tried advanced therapies, clinicians treating IBD, and researchers following emerging biologic therapies.
Sanofi and Teva presented additional Phase 2b data for their investigational TL1A-targeting drug duvakitug at the ECCO congress.
The results reported higher rates of clinical response, remission and endoscopic improvement versus placebo in both ulcerative colitis and Crohn’s disease groups, with the companies characterizing the treatment as generally well tolerated and without serious adverse events.
The companies highlighted that a higher dose helped about half of patients meet the trial’s primary endpoint at week 14 in each disease cohort, compared with lower placebo response rates. The firms and analysts say these mid-stage data support moving duvakitug into a Phase 3 program planned to begin later in the year.
These are mid-stage (Phase 2b) trial results presented at a medical congress; they support moving into Phase 3 testing but do not establish long-term safety or comparative effectiveness. The article is a news summary and cites analyst commentary.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A new antibody, duvakitug, showed higher remission/response rates than placebo in Phase 2b study data for both ulcerative colitis and Crohn’s disease, which could lead to a new treatment option if Phase 3 trials confirm...
This press release reports phase 2 evidence that a new experimental antibody (duvakitug) showed clinical, endoscopic, and histologic improvements in both UC and Crohn’s disease, which could lead to a new treatment option...
This reports phase 2b trial results showing a fixed-dose combination of two biologics (anti‑TNF + anti‑IL‑23) improved outcomes in people with refractory IBD compared with one biologic alone.
